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between 0% and 14% [5,16]. Our patient developed a 
transient ischemic attack, presumably due to a cardiac 
embolus. Although age- related thrombosis could not 
be ruled out, the patient could have benefited from 
cardiac surgery, which was not performed because of 
the presence of the oncocytoma. 
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Mycobacterium celatum as a cause of disseminated 
infection in an AIDS patient 
Clin Microbial Infect 1997; 3: 582-584 
Disseminated infections due to non-tuberculous myco- 
bacteria (NTM) are frequent in HIV-infected patients 
[l]. The Mycobacteriurn auiurn complex (MAC) accounts 
for most non-tuberculous disseminated infections, 
but recently species such as M. genavense, M. simiae and 
M.  haemophilum have emerged as potential pathogens in 
AIDS patients. M. celatum is a recently discovered micro- 
organism causing disseminated infection in immuno- 
compromised patients and could be misidentified [2]. 
We report a case of M.  celatum infection in an HIV- 
infected patient. 
A 30-year-old male intravenous drug abuser in- 
fected with HIV was admitted to the hospital with a 
7-day history of fever, chest pain, cough and yellowish 
sputum production, and significant weight loss during 
the last month. The CD4 T-cell count was 33 cells/pL. 
The patient, who had not received antiretroviral therapy, 
had been diagnosed as suffering cerebral toxoplasmosis 
and bilateral pneumonia 2 months previously. At the 
time of the present admission ocular cytomegalovirus 
(CMV) disease was also present. A chest X-ray showed 
perihiliar bilateral infiltrates. 
We processed three sputum specimens, urine 
cultures and blood cultures in the mycobacteriology 
laboratory. Sputa and urine were decontaminated by 
Karlson's procedure and blood cultures (BACTEC 
9240, Becton Dickinson Microbiology System, 
Cockeysville, Md) were processed using lysis-centri- 
fugation treatment [3]. Acid-fast bacilli (AFB) were 
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seen in sputum smears. The sputa showed a positive 
P C R  for M.  tuberculosis (MTB) (Aniplicor, Roche 
Diagnostics Systems) but the microorganism was not 
recovered by culture. The urine specimens processed 
were negative. Blood cultures showed growth of 
microorganisms which were identified as M.  celatum. 
Small, smooth, dome-shaped colonies, similar to MAC 
strains, grew only in the blood cultures after 41 days. 
The isolate was identified using two chemiluminescent 
DNA probes (Accuprobe, Gen Probe, San Diego), one 
specific for MAC and the other for M.  tuberculosis, 
according to the manufacturer’s recommendations. The 
amount of chemiluminescence emitted from hydrolysis 
of the DNA-RNA complex was estimated using a 
PAL luniinometer and quantified as relative light units 
(RLU). The cut-off point was established at 900 RLU. 
We obtained a negative result with the MAC probe 
and a weak positive result with the MTB probe 
(101 0 RLU). To confirm identification, gas-liquid 
chromatography (GLC) and PRA (PCR and restrict- 
ion pattern analysis) were performed at the Myco- 
bacteriology Reference Laboratory of one of the 
authors. The isolate was identified as M.  relatum. 
In spite of having received drugs which included 
rifampin, isoniazid and pyrazinamide, our patient died 
15 days after admission. Postmortem examination was 
not possible. 
In 1993, Butler et a1 described 24 isolates of a new 
species of mycobacterium and, using 16s rRNA as a 
basis, proposed the name M .  celatum, further differen- 
tiated into two genotypes 1 and 2 with a 10-nucleotide 
difference 141. Disseminated infection in AIDS patients 
was first reported in Italy, and more recently a retro- 
spective study with seven cases has been published 
by Tortoli et al, including the first two isolates [2,5,6]. 
O n  the basis of 16s rRNA sequencing, all these strains 
were assigned to the genotype 1. Fourteen clinical 
isolates causing disseminated infection in six patients 
have been reported in the UK. Analysis of 16s rRNA 
showed some nucleotide differences from the two 
genotypes previously described, and a new group of 
M.  ceelatum type 3 was proposed [7]. Zurawski et al have 
reported two cases of pneumonia and bacteremia in 
AIDS patients in the USA but information about 
genotypes was not available [8]. Only one report of 
cervical lymphadenitis in an imniunocompetent patient 
has been published [9]. 
M .  celatum is a new species of niycobacterium 
recently described as a slow-growing nonphoto- 
chromogenic organism whose cells are acid-fast, slender 
and predominantly rod-shaped. It does not form 
cords or branches. Colonies are predominantly small, 
smooth, dome-shaped and unpigmented and, like MAC 
strains, they become pale yellow when cultures are old 
(8-12 weeks) 141. Identification in the laboratory 
is problematic because biochemical tests give results 
similar to those produced by other mycobacteria ( M ,  
avium, M.  xenop4 [4,5]. Besides, DNA probes may also 
give misleading results because the MTB DNA probe 
sometimes shows cross-reactivity with M .  celatum. This 
in turn leads to false-positive results because the rRNA 
16s sequence is quite similar to that of M .  tuberculosis 
[lo]. Positive biochemical reactions for M .  celattrrn 
are 3- and 14-arylsulfatase, heat-stable catalase test, 
tellurite reduction and pyrazinamidase test. M .  celatum 
is negative for niacin production, Tween opacity nitrate 
reduction, hydrolysis of Tween-80 and urease activity 
[4]. M .  celaturn cannot be distinguished from M.  uuiitvn 
and M. xeuopi by thin-layer chromatography (TLC) 
but, although the GLC profiles of M.  xenopi and M.  
celatum are very similar, this technique allows them to 
be differentiated [4] on the basis of the relative amounts 
of secondary alcohols (2-ecosanol (2-OH-C20 : 0) and 
2-docosanol (2-OH-C22 : 0). 
Presumptive identification should include niicro- 
scopic ‘bird’s nest’ colony morphology, inability to 
grow at 45”C, a positive 3-day arylsulfatase test and 
resistance to rifabutin at 2 pg/mL. M .  celatuni may also 
be suspected when a non-pigmented mycobacterium 
behaves like MAC or M.  xenopi in biochemical tests and 
fails in hybridization with a genetic probe for MAC or 
gives negative or weak positive results with the MTB 
DNA probe. M .  celatum type 2 is the only genotype that 
has not shown cross reactivity with the commercial 
DNA probes for MTB identification [7,10]. Another 
point of interest is the positive result with P C R  for 
MTB. To our knowledge, there is only one previous 
report in which the Amplicor MTB P C R  Detection 
Kit was used. The 14 type 3 strains gave negative results 
[7]. Definitive identification must be performed on 
the basis of chromatographic mycolic patterns and 
molecular genetic analysis. 
Information on the antimicrobial susceptibility of 
M.  celatum is scarce and it has been described as variable 
in previous reports [4,5]. This variability can be attri- 
buted to the testing procedures used and the existence 
of three genetic subtypes within the same species 171. 
It is clear that M. celatum is susceptible to quinolones 
and clarithromycin and completely resistant to rifanipin, 
capreomycin, isoniazid and pyrazinamide [5]. The 
susceptibility pattern of our strain was determined 
by the proportions method [ I l l ,  and it was found to 
be resistant to isoniazid, rifanipin, streptomycin and 
ethambutol but susceptible to ethionamide. 
M .  celatum should be added to the list of N T M  
causing disseminated infection in AIDS patients. Special 
care is needed, as this microorganism can easily be 
missed or misinterpreted in the laboratory. 
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Recovery of Mycobacterium haemophilum skin infection 
in an HIV-I-infected patient after the start of antiretroviral 
triple therapy 
Clin Microbiol Infect 1997; 3: 584-585 
A 30-year-old Caucasian HIV-1-infected woman with 
a history of Pneumocystis carinii pneumonia presented 
with multiple painful cutaneous nodules on the extre- 
mities. Her CD4’ T-cell count was 50/mm3. She had 
recently returned from the island of St Maarten, where 
she had lived for 4 years. Her medication included co- 
trimoxazole 480 mg once daily as PCP prophylaxis, and 
zidovudine 200 mg three times daily with zalcitabine 
0.75 mg three times daily as antiretroviral therapy. 
Physical examination revealed tender, erythematous 
nodular lesions on the extremities, especially overlying 
the knee, the first metatarsal and elbows. A few ulcera- 
tive lesions discharged purulent material. Microscopic 
examination of biopsy specimens revealed a purulent 
inflammatory reaction with many acid-fast bacilli. A 
Mycobacterium marinum skin infection was suspected and 
the skin lesions resolved subsequent to treatment with 
doxycycline 200 mg once daily for two months. 
Two weeks after discontinuation of doxycycline, 
however, the skin lesions relapsed and rapidly pro- 
gressed despite retreatment with doxycycline. A second 
biopsy was performed and Mycobacterium haemophilum 
was identified using a nested P C R  of 16s rRNA gene 
fragments followed by direct sequence determination 
[l]. Cultures of the skin biopsy on Middlebrook 7H11 
medium supplemented with 60 pmol hemin revealed 
M.  haemophilum after 3 weeks of incubation at 30°C. 
Antibiotic susceptibility tests were not performed. The 
skin lesions failed to respond to treatment with cipro- 
floxacin 750 mg twice daily, rifampin 600 mg once 
daily and clarithromycin 500 mg twice daily for 8 
weeks, and progressed further despite a change of 
therapy to minocycline 100 mg once daily, rifabutin 
300 mg once daily and ethambutol 15 mg per kg once 
dailv. New mutilating skin lesions develoDed in the 
v 
masquerading as Mycobacterium x e w i  in patients with 
AIDS: an underdiagnosed problem? Clin Infect Dis 1997; 
Haase G, Skopnik H,  Batge S, Bottger EC. Cervical 
lymphadenitis caused by Mycobacteriurn celatum. Lancet 1994; 
face and in the right flexor side of the knee. Therefore, 
the regimen was changed to isoniazid 300 mg Once 
daily, ciprofloxacin 750 mg twice daily and cycloserine 
250 mg twice daily, and antiretroviral therapy was 
altered simultaneously to triple therapy of stavudine 
24: 140-3. 
8: 344: 1020-1. 
Butler WR, O’Connor SP, Yakrus MA, Gross WM. Cross- 
reactivity of genetic probe for detection of Mycobacterium 
(d4T) 30 mg twice lamivudine (3TC) mg 
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tuberculosis with newly described species Mycobacterium celatum. 
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patient’s condition improved remarkably and the skin 
lesion slowly healed with formation of scars. After 
2 months of treatment, all ulcerating skin lesions had 
disappeared except for a residual lesion in the knee. 
A reduction in the number of plasma HIV RNA 
copies from 12 000 copies per mL to values below the 
detection limit (1000 copies per mL, NASBA-QT; 
